

1646

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

1100 NEW YORK AVENUE, N.W., SUITE 600
WASHINGTON, D.C. 20005-3934

(202) 371-2600

FACSIMILE: (202) 371-2540; (202) 371-6566

ROBERT GREENE STERNE
EDWARD J. KESSLER
JORGE A. GOLDSTEIN
SAMUEL L. FOX
DAVID K.S. CORNWELL
ROBERT W. ESMOND
TRACY-GENE G. DURKIN
MICHELE A. CIMBALA
MICHAEL B. RAY


ROBERT E. SOKOHL
ERIC K. STEFFE
MICHAEL O. LEE
JOHN M. COVERT*
LINDA E. ALCORN
RAZ E. FLESHNER
ROBERT C. MILLONIG
STEVEN R. LUDWIG
MICHAEL V. MESSINGER

JUDITH U. KIM
TIMOTHY J. SHEA, JR.
DONALD R. MCPHAIL
PATRICK E. GARRETT
BARBARA A. PARVIS
STEPHEN G. WHITESIDE*
NOEL B. WHITLEY*
JEFFREY T. HELVEY*
RICHARD A. DUNNING, JR.

KIMBERLIN L. MORLEY
RALPH P. ALBRECHT
HEIDI L. KRAUS*
JEFFREY R. KURIN*
CARL B. MASSEY, JR.*
PATRICK D. O'BRIEN*
BRIAN S. ROSENBLUM*
LAWRENCE B. BUGAISKY
CRYSTAL D. SAYLES*
EDWARD W. YEE*

DONALD J. FEATHERSTONE**
KAREN R. MARKOWICZ**
GRANT E. REED**
VICTOR E. JOHNSON**
SERGE SIRA**
SUZANNE E. ZISKA**
BRIAN J. DEL BUONO**
CAMERON H. TOUSI**
VINCENT L. CAPUANO**
DONALD R. BANOWIT**
DAVID P. MAIVALD**

*BAR OTHER THAN D.C.
**REGISTERED PATENT AGENTS



October 9, 1998

Assistant Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Divisional Utility Patent Application
Appl. No. 09/033,662; Filed: March 3, 1998
For: **Human Vascular Endothelial Growth Factor 3**
Inventors: Jing-Shan HU *et al.*
Our Ref: 1488.1040001/RCM/AJK

Sir:

Transmitted herewith for appropriate action are the following documents:

1. First Supplemental Information Disclosure Statement;
2. 2 pages of Form PTO-1449; and
3. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

RECEIVED
TECH CENTER 1600/2900
98 OCT 14 AM 7:53

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Assistant Commissioner for Patents
October 9, 1998
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in black ink, appearing to read "Robert C. Millonig", written in a cursive style.

Robert C. Millonig
Attorney for Applicants
Registration No. 34,395

RCM/AJK/neh
Enclosures

P:\USERS\AKAMAGE\CASES\1488\104-1\100898-1st.sids-trl
SKGF Rev. 9/23/98 dcw

#4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HU *et al.*

Appl. No. 09/033,662

Filed: March 3, 1998

For: **Human Vascular Endothelial
Growth Factor 3**



Art Unit: 1646

Examiner: To be assigned

Atty. Docket: 1488.1040001/RCM/AJK

First Supplemental Information Disclosure Statement

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed on June 22, 1996 in connection with the above-captioned application. Copies of the documents were cited by or submitted to the Office in Application No. 08/469,641, filed June 6, 1995, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

RECEIVED
TECH CENTER 1600/2900
98 OCT 14 AM 7:53

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that was cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

This First Information Disclosure Statement is being filed within three months of the U.S. filing date or before the mailing date of a first Office Action on the merits. No statement or fee is required.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this pleading is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN, & FOX P.L.L.C.



Robert C. Millonig
Attorney for Applicants
Registration No. 34,395

Date: Oct. 9, 1998

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600